Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Covington
Johnson and Johnson
Daiichi Sankyo
Moodys
Fish and Richardson
McKinsey
UBS

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,784,869

« Back to Dashboard

Which drugs does patent 8,784,869 protect, and when does it expire?

Patent 8,784,869 protects NATESTO and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.
Summary for Patent: 8,784,869
Title:Controlled release delivery system for nasal applications and methods of treatment
Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Inventor(s): Mattern; Claudia (Stans, CH)
Assignee: Mattern Pharma AG (Vaduz, LI)
Application Number:13/547,774
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 8,784,869

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Aytu Bioscience Inc NATESTO testosterone GEL, METERED;NASAL 205488-001 May 28, 2014 RX No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,784,869

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03025769Nov 11, 2003

Non-Orange Book US Patents Family Members for Patent 8,784,869

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,784,882 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
2,014,073,618 ➤ Sign Up
9,579,280 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
9,238,072 Controlled release delivery system for nasal applications and method of treatment ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Express Scripts
Cantor Fitzgerald
QuintilesIMS
Farmers Insurance
McKinsey
Chinese Patent Office
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.